KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Other Non-Current Assets (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Other Non-Current Assets for 15 consecutive years, with $5.4 billion as the latest value for Q4 2023.

  • On a quarterly basis, Other Non-Current Assets changed N/A to $5.4 billion in Q4 2023 year-over-year; TTM through Dec 2023 was $5.4 billion, a N/A change, with the full-year FY2023 number at $5.4 billion, changed N/A from a year prior.
  • Other Non-Current Assets was $5.4 billion for Q4 2023 at Bristol Myers Squibb, up from $54.0 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $7.0 billion in Q4 2020 to a low of $53.0 million in Q1 2023.
  • A 5-year average of $1.8 billion and a median of $373.0 million in 2021 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: skyrocketed 226.28% in 2019, then tumbled 81.9% in 2020.
  • Bristol Myers Squibb's Other Non-Current Assets stood at $6.6 billion in 2019, then rose by 6.28% to $7.0 billion in 2020, then plummeted by 95.17% to $339.0 million in 2021, then tumbled by 34.22% to $223.0 million in 2022, then skyrocketed by 2308.07% to $5.4 billion in 2023.
  • Per Business Quant, the three most recent readings for BMY's Other Non-Current Assets are $5.4 billion (Q4 2023), $54.0 million (Q3 2023), and $53.0 million (Q2 2023).